ARCA biopharma, Inc. (NASDAQ:ABIO) Files An 8-K Other Events
Item 8.01.
|
Other Events. |
On March 6, 2017, ARCA biopharma, Inc. (ARCA) provided a
GENETIC-AF clinical trial update.The press release is furnished
as Exhibit 99.1 hereto, the contents of which are incorporated
herein by reference.
Section 9 Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit Number |
Description |
|
99.1 |
Press Release titled ARCA biopharma Announces |
About ARCA biopharma, Inc. (NASDAQ:ABIO)
ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company’s lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules, primarily the neurotransmitter norepinephrine (NE), which activate these receptors. The Company is conducting a Phase IIB/III clinical trial of Gencaro, known as GENETIC-AF. ARCA biopharma, Inc. (NASDAQ:ABIO) Recent Trading Information
ARCA biopharma, Inc. (NASDAQ:ABIO) closed its last trading session up +0.05 at 2.60 with 17,695 shares trading hands.